NCT00731016

Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 3 Years
• Healthy volunteers: Not accepted

Summary

We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest infringements of the disease, to prolong the life of the children, and in a more general way, aim at improving their living conditions.

Conditions

• Hutchinson-Gilford Progeria Syndrome

Interventions

Type	Name	Description
DRUG	Zoledronic acid, pravastatin	Pravastatin : 10 mg daily Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule : * injection 1, S1: 0.0125 mg/kg of zoledronic acid * injection 2, S6: 0.025 mg/kg of zoledronic acid * injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid

Timeline

• Start date: 2008-10-01
• Primary completion: 2013-04-01
• Completion: 2013-07-01
• First posted: 2008-08-08
• Last updated: 2013-07-08

Locations

1 site across 1 country: France